Novartis AG (NOVN.SW)
| Previous Close | 88.87 |
| Open | 88.86 |
| Bid | 89.06 x 0 |
| Ask | 89.07 x 0 |
| Day's Range | 88.63 - 89.26 |
| 52 Week Range | 79.21 - 94.52 |
| Volume | |
| Avg. Volume | 3,357,497 |
| Market Cap | 181.739B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 22.10 |
| EPS (TTM) | 4.03 |
| Earnings Date | Jul 18, 2024 |
| Forward Dividend & Yield | 3.30 (3.71%) |
| Ex-Dividend Date | Mar 07, 2024 |
| 1y Target Est | 86.92 |
ZacksWhy This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ReutersMorphosys says takeover by Novartis on course after report of drug safety concern
BERLIN (Reuters) -Morphosys said its takeover by Novartis is still expected to close in the first half of this year, after a news report on a possible drug safety risk knocked the German biotechnology company's stock price on Monday. Morphosys' statement came after a report by specialist website STAT News, citing two people familiar with the matter, of a safety issue with its experimental drug pelabresib, which is being developed to treat myelofibrosis, a rare type of blood cancer affecting the bone marrow.
ZacksPharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
